Tolerance and acceptability of Norplant® contraceptive devices;Tolérance et acceptabilité des implants contraceptifs Norplant®: Expérience au CHU A. Le Dantec de Dakar (Sénégal)

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 31, Issue 8, 2002, Pages 765-771

  Ba, M G ^a   Moreau, J C ^a   Diadhiou, F ^a  

^a Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

Author keywords

Acceptability; Norpfant ; Senegal; Tolerance

Indexed keywords

AGE; AMENORRHEA; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; BODY WEIGHT; CONTRACEPTION; CONTRACEPTIVE DEVICE; CONTROLLED STUDY; DEVICE REMOVAL; FAMILY; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HUMAN; HYPERTENSION; IMPLANT; INSOMNIA; MENSTRUATION; PARITY; PATIENT SATISFACTION; PREGNANCY; PROSPECTIVE STUDY; SENEGAL; TEACHING HOSPITAL; TIME; TREATMENT FAILURE; VERTIGO;

ADOLESCENT; ADULT; AMENORRHEA; ASTHENIA; CONTRACEPTION; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVONORGESTREL; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SENEGAL; SILICONE ELASTOMERS; UTERINE HEMORRHAGE;

EID: 0036928254     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Centre de Recherche pour le Développement International (CRDI). Choix et défis. La recherche d'un implant contraceptif, un effort mondial, 84 pages.
2. Sivin I, Diaz S, Holma P, Alvarez-Sanchez F, Robertson DN. A four-year clinical study of Norplant® implants. Studies in Family Planning 1983; 14: 184-91.
3. Lankoandé J, Ouédraogo A, Dao B, Ouédraogo CMR, Bonané B, Touré B. et al. Evaluation de la pré-introduction de la contraception par les implants sous-cutanés de lévonorgestrel au Burkina Faso. Dakar Medical 1998; 43: 79-82.
4. Satayapan S, Kanchanasinith K, Varakamin S. Perceptions and acceptability of Norplant® implants in Thailand. Studies in Family Planning 1983; 14: 170-6.
5. Hamzaoui R, Boulehia N, Gorgoh K, Derbel S, Chadi R, Gueddana N. Prise en charge des troubles du cycle menstruel des femmes sous Norplant®: Expérience de la clinique de planning familial de l'Ariana. Rev Maghr Endocrino 1995; 1: 220-3.
6. Singh K, Viagas OAC, Ratnam SS. A three-year clinical evaluation of Norplant® in Singaporean acceptors. Advances in Contraception 1990; 6: 1-9.
7. Aguillaume CJ, Sivin I, Bardin CW. Les implants Norplant®: La premiére génération de contraceptifs sous-cutanés féminins. Références en Gynécologie-Obstétrique 1994; 2: 268-80.
8. Ba MG, Moreau JC, Sokal D, Dunson R, Dao B, Kouedou D, Diadhiou F. A 5-year clinical evaluation of Norplant® implants in Senegal. Contraception 1999; 59: 377-81.
9. Ping T, Shuhua Q, Huimin F, Smith HL. Acceptance, efficacy and side effets of Norplant®: Implants in four countries in North China. Studies in Family Planning 1997; 28: 122-31.
10. Boukhris R, Ben Slama C, Boukhris L, Mrad S, Khrouf M, Chelli H, et al. Systémes de libération continue d'hormones steroïdes: Etude du Norplant® en Tunisie. Rev Maghr Endocrino 1995; 1: 76-80.
11. Moreau JC, Ba MG, Sangaré M, Israél A, Sokal D, Diadhiou F. Contraception par les implants sous-cutanés Norplant®: À propos de 300 cas. Contraception Fertil Sex 1998; 26: 297-9.
12. Coukell AJ, Balfour JA. Levonorgestrel subdermal implants: A review of contraceptive efficacy and acceptability. Drugs 1998; 55: 861-87.
13. Sivin I, Robertson DN, Stern J, Croxatto HB, Diaz S, Coutinho E, et al. Norplant®: Reversible implant contraception. Studies in Family Planning 1980; 11: 227-35.